

Comfort. Compassion. Care.

January 6, 2021

Dear Grandview families and friends:

The recent announcements by the provincial government identifying long term care residents and staff as priority target groups for the COVID-19 vaccine is exciting. We have all worked tirelessly to protect our community's most vulnerable from COVID-19 – and now there is an additional tool to keep our LTC family safe.

We have learned through our management of the pandemic from onset to the current status, that changes in Provincial Directives, infection prevention and control interventions and new initiatives happen swiftly and often with very little notice. We anticipate that this too will be the case for vaccine distribution and subsequent administration. We want to be prepared with needle in hand when the vaccine becomes available to Grandview Lodge.

In an effort to prepare for the eventual distribution of the vaccine we are implementing a COVID-19 vaccination strategy in the home. This will include a proactive approach to gathering resident information, consulting with the resident's physician to obtain an order for vaccination for eligible residents and obtaining consent from residents/POA.

The greatest challenge associated with this proactive approach is that we will not know which vaccine will be earmarked to Grandview Lodge residents. For this reason we will be asking for residents/POA to consent to administration of "COVID-19 vaccine". That being said, residents/POA have a right to refuse either vaccine or both.

The vaccine is voluntary, but our residents are strongly encouraged to get vaccinated. The Pfizer-BioNTech COVID-19 Vaccine will likely be available first with the expectation that the Moderna COVID-19 Vaccine will follow at a later date but we are unable to confirm which will be offered to our home first or the wait time for the alternate to be offered. Serious side effects reported at this time are at a minimum and are not unlike those associated with other vaccines or medications. In order for the body to build up protection against the virus, people will need to receive two doses of this vaccine. Please read the fact sheets attached to help you make an informed decision about COVID-19 vaccination for the resident so that you can provide your direction when we call for consent. You can also visit Ontario.ca to find reputable, updated information about the COVID-19 vaccine, or visit Public Health Ontario or Health Canada's websites. Please contact the Registered Staff on your resident's unit if you have concerns regarding a medical condition.

We are working closely with the Haldimand Norfolk Public Health Unit to ensure we are prepared to rollout the vaccine as soon as it becomes available. We are populating an enrolment form for each resident. In an effort to facilitate vaccination, it is mandatory that we complete this form in full regardless of your decision.

Eligibility Information

Individuals under 18 years of age are not eligible for the Moderna COVID-19 Vaccine

- Individuals under 16 years of age are not eligible for the Pfizer COVID-19 Vaccine
- Individuals who are allergic to any of the ingredients found in the <u>Moderna COVID-19</u>
 <u>Vaccine Monograph</u> are not eligible
- Individuals who are allergic to any of the ingredients found in the <u>Pfizer COVID-19 Vaccine</u> Monograph
- Individuals who have symptoms that could be COVID-19; are not eligible and should get a COVID-19 test

If you have questions related to the overall Ontario vaccination plan we recommend you visit Ontario.ca for details about our province's Ontario.ca for details about our province's Ontario.ca for details about our province's Ontario.ca for details about our province's related to the overall Ontario or Ontario.

Thank you for your incredible support of our efforts to contain the spread of COVID-19 in our Home. Your participation in this next stage of the pandemic will be a hopeful step in protecting the community we all love.

Stay Well Jennifer

Information Sheet for Pfizer-BioNTech COVID-19 Vaccine COVID-19 mRNA Vaccine, Suspension for Intramuscular Injection

This sheet provides an overview of the vaccine. Please refer to the product monograph. ⁴

Dec 17, 2020

How does Pfizer-BioNTech COVID-19 Vaccine work?

- The vaccine causes the body to produce protection (such as antibodies) that prevent the COVID-19 virus from entering cells.
- The vaccine uses a new method (messenger RNA mRNA, the genetic code for a piece of the virus) to help the body to protect against the virus.
- mRNA vaccines do not contain the live virus.
- The vaccine is given by injection with a needle in the upper arm and will require two doses given 21 days apart.
- COVID-19 cannot be acquired solely by the administration of the vaccine.

Based on studies in about 44,000 participants, the Pfizer-BioNTech COVID-19 vaccine was 95% effective in preventing COVID-19 beginning one week after the second dose.

As with any vaccine, Pfizer-BioNTech COVID-19 Vaccine may not fully protect all those who receive it. Even after both doses of the vaccine have been administered, it is important to continue to follow the recommendations of local public health officials to prevent spread of COVID-19.

Who should not receive Pfizer-BioNTech COVID-19 Vaccine?

- Those with a history of allergy to any of the ingredients in this vaccine
- Presence of any symptoms that could be due to COVID-19. Seek advice from a healthcare professional to determine eligibility to receive the vaccine.
- People under 16 years old, pregnant women and immunocompromised people are not recommended to get the vaccine at this time.

Additional precautions to consider (consult with your healthcare provider)

- Complications following previous administration of Pfizer-BioNTech COVID-19 Vaccine such as an allergic reaction or breathing problems.
- · Presence of a weakened immune system
- · History of bleeding problems, easy bruising or use a blood thinning medication
- Pregnancy, suspected pregnancy or planning to become pregnant
- Currently breast-feeding
- COVID-19 vaccines have not yet been tested in people under 16 years old, pregnant women or those with immunocompromising conditions.

Dosage form

White to off-white suspension (once diluted) provided in a multiple dose vial of 5 doses. After dilution, the vial contains 5 doses of 0.3 mL, with 30 micrograms mRNA each.



medicalpharmacies.com

Information Sheet for Pfizer-BioNTech COVID-19 Vaccine COVID-19 mRNA Vaccine, Suspension for Intramuscular Injection (cont.)

Ingredients

Medicinal ingredient: mRNA Non-medicinal ingredients:

- ALC-0315 = ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)
- ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide
- · 1,2-Distearoyl-sn-glycero-3-phosphocholine
- Cholesterol
- · Dibasic sodium phosphate dihydrate
- · Monobasic potassium phosphate
- Potassium chloride
- Sodium chloride
- Sucrose
- · Water for injection

Possible side effects

Like all vaccines, Pfizer-BioNTech COVID-19 Vaccine can cause side effects. The following side effects may occur:

VERY COMMON May affect more than 1 in 10 people	UNCOMMON May affect up to 1 in 100 people
 Pain at injection site Tiredness Headache Muscle pain Chills Joint pain Fever 	 Enlarged lymph nodes Allergic reaction include: Hives (bumps on the skin that are often very itchy) Swelling of the face, tongue or throat; Difficulty breathing

If a patient experiences a side effect following immunization, please complete the Adverse Events Following Immunization (AEFI) Form applicable to the province/territory and send it to the local Health Unit.

Storage

- -80 to -60 degrees Celsius for 6 months
- Stable at 2 to 8 degrees Celsius x 5 days
- Prior to dilution, the multiple dose vial may be stored at room temperature for no more than 2 hours.
- · Once reconstituted, use within 6 hours



Information Sheet for Pfizer-BioNTech COVID-19 Vaccine COVID-19 mRNA Vaccine, Suspension for Intramuscular Injection (cont.)

Administration

Usual dose

- Pfizer-BioNTech COVID-19 Vaccine is given after dilution as an injection of 0.3 mL into the deltoid muscle of the upper arm.
- Two injections are needed, given 21 days apart. Administration of both doses are required in order to ensure efficacy of the vaccine.
- Visually inspect each dose in the dosing syringe prior to administration. The diluted vaccine will be an off-white suspension.

During the visual inspection:


Verify the final dosing volume of 0.3 mL, and confirm there are no particulates and that no discolouration is observed.


If the visual inspection fails, do not administer the vaccine.


Administer Pfizer-BioNTech COVID-19 Vaccine intramuscularly in the deltoid muscle.
 Do not inject the vaccine intravascularly, subcutaneously or intradermally.

Handling instructions

Must be reconstituted before use. View PDF







Resources

- Health Canada website: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccinestreatments/vaccines/pfizer-biontech.html
- 2) Manufacturer's website: www.pfizer.ca
- 3) Pfizer Medical Information: 1-800-463-6001
- 4) Product monograph: https://covid-vaccine.canada.ca/info/pdf/pfizer-biontech-covid-19-vaccine-pm1-en.pdf
- 5) https://www2.gov.bc.ca/gov/content/safety/emergency-preparedness-response-recovery/covid-19-provincial-support/vaccines



Information Sheet for Moderna (mRNA-1273) COVID-19 Vaccine

This sheet provides an overview of the vaccine. Please refer to the product monograph. ¹

Dec 30, 2020

How does Moderna (mRNA-1273) COVID-19 Vaccine work?

- The vaccine causes the body to produce protection (such as antibodies) that prevent the COVID-19 virus from entering cells.
- The vaccine uses a new method (messenger RNA mRNA, the genetic code for a piece of the virus) to help the body to protect against the virus.
- mRNA vaccines do not contain the live virus.
- The vaccine is given by injection with a needle in the upper arm and will require two doses given 28 days apart.
- COVID-19 cannot be acquired solely by the administration of the vaccine.

As with any vaccine, Moderna COVID-19 Vaccine may not fully protect all those who receive it. Even after both doses of the vaccine have been administered, it is important to continue to follow the recommendations of local public health officials to prevent spread of COVID-19.

Who should not receive Moderna (mRNA-1273) COVID-19 Vaccine?

- · Those with allergies to any ingredients to the vaccine
- People under 18 years old
- Symptomatic individuals with confirmed or suspected SARS-CoV-2 infection or those with symptoms of COVID-19.
- · Individuals who received another vaccine (not a Moderna COVID-19 vaccine) in the past 14 days

Additional precautions to consider (consult with your healthcare provider)

- Complications following previous administration of Moderna COVID-19 Vaccine such as an allergic reaction or breathing problems.
- · Presence of a weakened immune system
- · History of bleeding problems, easy bruising or use a blood thinning medication
- This COVID-19 vaccine has not yet been tested in people under 18 years old, pregnant women, or those with immunocompromising conditions or are receiving immunosuppressant therapy.

Ingredients

- Messenger ribonucleic acid (mRNA)
- Acetic Acid
- Cholesterol
- Lipid SM-102
- Polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG]
- 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC])
- Tromethamine
- · Tromethamine hydrochloride
- Acetic acid
- Sodium acetate
- Sucrose



Information Sheet for Moderna (mRNA-1273) COVID-19 Vaccine (cont.)

Dosage form

The Moderna COVID-19 Vaccine is administered intramuscularly as a series of two doses (100mcg/0.5 mL each) 28 days apart.

Possible side effects

The most frequently reported adverse reactions after any dose were pain at the injection site (92.0%), fatigue (70.0%), headache (64.7%), myalgia (61.5%) and chills (45.4%)

If a patient experiences a side effect following immunization, please complete the Adverse Events Following Immunization (AEFI) Form applicable to the province/territory and send it to the local Health Unit.

Storage

- Store frozen between -25° to -15°C (-13° to 5°F). Store in the original carton to protect from light.
- Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 30 days prior to first use.
- Unpunctured vials may be stored between 8° to 25°C (46° to 77°F) for up to 12 hours.

Preparation

- Thaw each vial before use in refrigerated conditions between 2°C to 8°C for 2 hours and 30 minutes, then let each vial stand at room temperature for 15 minutes before administration.
 Alternatively, thaw each at room temperature between 15°C and 25°C for 1 hour.
- It must not be reconstituted, mixed with other medicinal products, or diluted.
- Do not refreeze once thawed.
- · Swirl vial gently after thawing and between each withdrawal. Do not shake.

Administration

Moderna COVID-19 Vaccine is a suspension given as an injection of 0.5mL intramuscularly into the deltoid muscle of the upper arm. Two injections are needed, 28 days apart.

- The Moderna COVID-19 Vaccine is a white to off-white suspension and may contain white or translucent product-related particulates. Visually inspect each dose for foreign particulate and/or discoloration. If either of these conditions exist, the vaccine should not be administered.
- Withdraw each 0.5mL dose of vaccine from the vial using a new sterile needle and syringe. The dose should be administered intramuscularly in the upper deltoid.

Use with other vaccines

Current recommendations are that the Moderna COVID-19 Vaccine should not be administered if another vaccine was administered within the past 14 days.

Resources

- Product Monograph. https://pdf.hres.ca/dpd_pm/00059305.PDF
- Manufacturer Website. https://www.modernatx.com/
- 3. COVID-19 Vaccines. https://tools.cep.health/tool/covid-19-vaccines/#about-the-moderna-mrna-vaccine

